| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dacb2e3d1021bbf7f6fddb2efca6f1e2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2015-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9495a21ef163391d20d11b766bc5b0cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_785f5aed1b132ace840c0717cb5f9a3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74e72afecf322d8d952394359d113ee0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df56b513a01fbc309e93b51f8e9dc875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0acc389fdb5ffa982062e2bb45c5060c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe6c4a1713618f5a1a632b2fed3c67e4 |
| publicationDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9700531-B2 |
| titleOfInvention |
Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease |
| abstract |
The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110467680-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110467680-A |
| priorityDate |
2012-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |